Pharmaceutical Environmental Risk Assessment

Home→ERA Profiles → Cefixime→

Cefixime Environmental Risk Assessment (ERA) report

Project-specific environmental risk assessment (ERA) support for human medicinal products and regulatory submissions.

CAS Registry Number
79350-37-1
Molecular formula
C16H15N5O7S2
Molecular weight
453.5 g/mol
Drug class
Third-generation oral cephalosporin beta-lactam antibacterial
Mechanism of action
Binds penicillin-binding proteins and inhibits the final transpeptidation step of bacterial peptidoglycan cell-wall synthesis, producing bactericidal activity against susceptible organisms.
Indications / reported uses
  • Treatment of infections caused by cefixime-susceptible bacteria, including selected urinary-tract infections, otitis media, pharyngitis/tonsillitis and acute exacerbations of chronic bronchitis
  • Treatment of uncomplicated gonorrhoea only where recommended by current local antimicrobial guidance and susceptibility patterns; exact approved indications vary by jurisdiction

Sources: US DailyMed — Cefixime · NHS — Cefixime · FDA product information

View request basketPrefer email? info@toxwriter.com
Phase IPhase II where requiredEU / UK / other markets
Assessment scope

Environmental Risk Assessment (ERA)

ToxWriter provides project-specific support for the Cefixime Environmental Risk Assessment (ERA) (the Cefixime ERA report). The required pathway is determined by the medicinal product, active-substance form, route, intended market, use assumptions and available environmental evidence.

Assessment may cover

  • Product, active-substance identity, formulation, route and intended-market review.
  • Phase I environmental exposure screening and applicable trigger evaluation.
  • Phase II environmental fate and ecotoxicity assessment where required by the applicable pathway.
  • PEC/PNEC risk characterisation and PBT/vPvB considerations where relevant and supported by evidence.
  • Data-gap analysis, study strategy, assumptions and scientific reporting.
ERA regulatory framework

The EMA guideline sets out the EU framework for environmental risk assessment of human medicinal products. MHRA guidance describes UK expectations; the applicable scope depends on the product and submission context.